Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

 
• By Alaric DeArment

The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent. 

Galderma announced results from the Phase III OLYMPIA 2 trial of nemolizumab in prurigo nodularis • Source: Shutterstock

More from Clinical Trials

More from R&D